Bicara Therapeutics (BCAX) Change in Accured Expenses (2023 - 2026)

Bicara Therapeutics has reported Change in Accured Expenses for 4 years, with the latest figure at -$1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 141.29% year-over-year to -$1.4 million; the trailing twelve-month figure through Mar 2026 stood at $3.0 million (down 68.14% YoY), and the FY2025 full-year result was $7.7 million, up 15.54% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$1.4 million, down from $6.3 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $15.1 million in Q4 2023, with the low at -$1.8 million in Q2 2025.
• Historically, Change in Accured Expenses has averaged $2.8 million across 4 years, with a median of $1.2 million in 2024.
• Annual changes were most pronounced in 2025 — Change in Accured Expenses jumped 692.03% — and 2026, when it tumbled 141.29%.
• Bicara Therapeutics' Change in Accured Expenses stood at $15.1 million in 2023, then plunged by 60.9% to $5.9 million in 2024, then gained by 7.24% to $6.3 million in 2025, then sank by 121.4% to -$1.4 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.4 million (Q1 2026), $6.3 million (Q4 2025), and -$168000.0 (Q3 2025), per Business Quant data.